Receptor News and Research

RSS

Machine learning identifies natural compound to treat lung disease

A new study published in Engineering has combined machine learning (ML) and experimental validation to identify dihydromyricetin (DHM), a natural flavonoid, as a potent inhibitor of the TGF-β/ALK5 signaling cascade with therapeutic potential for idiopathic pulmonary fibrosis (IPF).

16 Jun 2026

New single-protein analysis technique provides unprecedented information on scramblases

A new single-protein analysis technique gives researchers an unprecedented ability to study proteins called scramblases, which have critical roles in biology.

16 Jun 2026

Neutrophils reduce the effectiveness of cancer immunotherapy in mice

A type of white blood cell in the immune system, known as neutrophils, can make cancer immunotherapy less effective. This is shown in a new study from Karolinska Institutet published in the journal Immunity.

15 Jun 2026

Light-controlled molecular switch wakes lung cancer cells for treatment

Researchers from ETH Zurich have developed a molecular switch that is controlled by light. It wakes lung cancer cells up from a protective dormant state so that they are more accessible for treatment.

15 Jun 2026

Glucosamine may worsen Alzheimer’s by fueling abnormal brain glycosylation

A Nature Metabolism study identifies brain hyperglycosylation as a metabolic driver of Alzheimer’s disease, with increased N-glycan biosynthesis seen in human AD tissue and mouse models. Reducing glycosylation improved memory in AD mice, while glucosamine worsened memory deficits in 5xFAD mice and was associated with poorer outcomes in dementia patients.

14 Jun 2026

GLP-1 therapy associated with more dizziness and fainting

Northwestern Medicine scientists have identified a safety concern associated with GLP-1 drugs. Using health record data, the research team tracked more than 42,000 adults already taking at least two types of blood pressure medications.

14 Jun 2026

Physical activity declines after starting GLP-1 obesity treatments

Adults with obesity losing weight with glucagon-like peptide-1 (GLP-1) receptor agonist medications significantly decreased their physical activity, which is essential to protect muscle, according to a study being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

14 Jun 2026

Major NIH grant helps establish the Oklahoma Center of ImmunoEngineering

The University of Oklahoma has received an $11.5 million award from the National Institutes of Health to establish the Oklahoma Center of ImmunoEngineering, a new research center designed to accelerate the study and treatment of diseases rooted in the immune system.

12 Jun 2026

Study identifies immune pathway driving long-term concussion damage

Traumatic brain injuries (TBI) - even mild concussions - may trigger a chain reaction in the brain that disrupts neuronal communication, long-term memory, and cognition, according to University of California, Riverside research investigating how the brain's immune system responds after injury.

12 Jun 2026

No link between cat ownership and asthma flare-ups in children

A study of over 30,000 children reveals no link between cat exposure and asthma outcomes, challenging previous concerns about pet ownership and asthma control.

12 Jun 2026

Oral semaglutide improves blood sugar, weight, and liver markers in real-world diabetes care

A nationwide Finnish registry study of 7,249 GLP-1RA-naïve adults with type 2 diabetes found that once-daily oral semaglutide was associated with 12-month improvements in HbA1c, body weight, lipid markers, and ALT.

11 Jun 2026

Oral GLP-1 drug elecoglipron helps adults lose up to 11.8% body weight

Once-daily oral elecoglipron produced dose-dependent weight loss in adults with obesity or overweight without diabetes, with mean reductions reaching 10.5% at 26 weeks and 11.8% at 36 weeks in the highest-dose weekly-titration group. The phase 2 trial found no evidence of a weight-loss plateau by 36 weeks, while gastrointestinal adverse events were common but generally manageable.

11 Jun 2026

Collagen exists as liquid droplets inside living cells, study reveals

Collagen, the protein that builds skin, bones, tendons and organs, exists inside cells as a liquid-like droplet rather than the long, rigid rod seen in textbooks over the last half century, according to a new study from the Centre for Genomic Regulation (CRG) in Barcelona.

11 Jun 2026

Western diet weakens the gut’s nervous system through iron-dependent damage

A JCI study found that exposure to a Western diet in mice and to palmitic acid in murine and ex vivo human enteric nervous system models triggered ferroptosis, characterized by iron loading, lipid peroxidation, mitochondrial stress, and enteric neuronal loss. Boosting Nrf2 signaling protected enteric neurons and prevented Western diet-induced delayed colonic transit in mice, pointing to a potential pathway linking dietary fat exposure to gut motility dysfunction.

10 Jun 2026

Researchers uncover immune loop driving Sjögren's disease progression

Sjögren's disease is a widespread chronic autoimmune disorder that attacks the body's own glands, yet its underlying disease mechanisms remain poorly understood.

10 Jun 2026

Study identifies an important driver of inflammatory bowel disease

Researchers at the Nuffield Department of Medicine, University of Oxford, together with Newcastle University's Translational and Clinical Research Institute and the Department of Immunology at Cambridge University Hospitals NHS Foundation Trust, have identified an important driver of inflammatory bowel disease (IBD).

10 Jun 2026

Why Andes hantavirus is not the next COVID-19

Research highlights fundamental differences between Andes hantavirus and SARS-CoV-2, emphasizing distinct transmission routes and public health implications.

10 Jun 2026

GLP-1 medicines may cut clot-related risks in chronically inflamed patients

In a target trial emulation using OneFlorida+ electronic health record data, GLP-1 receptor agonist use in adults with obesity and autoimmune disease was linked to lower hazards of pulmonary embolism, venous thromboembolism, stroke/TIA, emergency department visits, and all-cause mortality.

10 Jun 2026

Obesity drug mazdutide reduces weight and waist size in major trial

Once-weekly 9 mg mazdutide produced clinically meaningful weight loss in Chinese adults with obesity, reducing body weight by 16.65% after 60 weeks versus 1.50% with placebo. The phase 3 GLORY-2 trial also found improvements in waist circumference, systolic blood pressure, and lipid markers, but gastrointestinal adverse events were common.

9 Jun 2026

Excess weight identified as key driver for cardiovascular-kidney-metabolic syndrome

The first-ever clinical guideline for cardiovascular-kidney-metabolic syndrome, or CKM syndrome, identifies excess weight, especially in the abdomen, as a key driver for the syndrome. T

9 Jun 2026